Skip to main content
Clinical Trials/EUCTR2012-004956-12-IT
EUCTR2012-004956-12-ITActive, not recruitingPhase 1

A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and correlative science studies attempting to identify predictors of response - Neoadjuvant eribulin

ISTITUTO NAZIONALE PER LA CURA TUMORI0 sites48 target enrollmentStarted: January 11, 2013Last updated:
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
48

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • tumor >= 2 cm
  • HER2 negative
  • ER PgR negative
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 48
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 48

Exclusion Criteria

  • prior treatment for breast cancer
  • metastatic cancer
  • bilateral invasive breast cancer
  • multicentric breast cancer
  • pre-existing peripheral neuropathy

Investigators

Sponsor
ISTITUTO NAZIONALE PER LA CURA TUMORI

Similar Trials

Active, not recruiting
Phase 1
An open label, single-arm, phase 2 study od neoadjuvant nivolumab and nab-paclitaxel before cystectomy for patients with muscle-invasive bladder cancermuscle-invasive bladder cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2020-005050-20-ITOSPEDALE SAN RAFFAELE29
Recruiting
Phase 2
A study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in patients affected by high-risk prostate cancer
2024-514580-26-00Ospedale San Raffaele S.r.l.59
Recruiting
Phase 2
A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer1001799010017991gastric cancerstomach cancer
NL-OMON53113Antoni van Leeuwenhoek Ziekenhuis207
Active, not recruiting
Phase 1
A randomised trial for gastric cancer with neo-adjuvant chemotherapy, chemoradiotherapy and surgery
EUCTR2015-004627-31-NLThe Netherlands Cancer Institute
Active, not recruiting
Phase 1
A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinomahigh risk, surgically resectable, stage III Cutaneous Squamous Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10041834Term: Squamous cell carcinoma of skinSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2019-001469-34-ITFONDAZIONE MELANOMA ONLUS25